Sensei Biotherapeutics Q3 net loss $7.1M; cash $72M; SNS-101 Phase 1 data positive

Sensei Biotherapeutics, Inc.

2023-Q3 EPS reported -$0.92

Net loss $7.1M in Q3 2023 vs $13.4M in Q3 2022; cash $72.0M as of Sept 30, 2023, down from $107.1M at Dec 31, 2022.
R&D expenses $3.8M vs $9.2M YoY; G&A $3.9M vs $4.8M; cash runway expected into H2 2025.
SNS-101 Phase 1 data at SITC: no cytokine release syndrome, no dose-limiting toxicities, dose-proportional pharmacokinetics.
Enrollment ahead of schedule: 17 patients treated; monotherapy dose escalation at 15 mg/kg; combination arm cleared 3 mg/kg.
Apped Stephanie Krebs as CBO; SNS-201 and SNS-102 lead candidates selected; milestones: combo data Q1 2024, monotherapy topline Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sensei Biotherapeutics, Inc. reported financial results for the third quarter ended September 30, 2023.

Period: the third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the quarter ended September 30, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Sensei Biotherapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-271921

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.